Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in korean patients with major depressive disorder

Neuropsychobiology

Volumn 66, Issue 4, 2012, Pages 221-229

  Won, Eun Soo ^a   Chang, Hun Soo ^b   Lee, Hwa Young ^c   Ham, Byung Joo ^a   Lee, Min Soo ^a,b  

^a College of Medicine   (South Korea)

^b Korea University   (South Korea)

^c Soonchunhyang University   (South Korea)

Author keywords

Escitalopram treatment response; Major depressive disorder; Serotonin transporter linked polymorphic region

Indexed keywords

ESCITALOPRAM; LORAZEPAM; SEROTONIN TRANSPORTER;

ADULT; AGED; ALLELE; ARTICLE; ASIAN; BEDTIME DOSAGE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAMILTON SCALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84867665768     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000341876     Document Type: Article

References (62)

1. Serretti A, Kato M, De Ronchi D, Kinoshita T: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12:247-257.
2. Blakely RD, Ramamoorthy S, Schroeter S, Qian Y, Apparsundaram S, Galli A, DeFelice LJ: Regulated phosphorylation and trafficking of antidepressant- sensitive serotonin transporter proteins. Biol Psychiatry 1998; 44:169-178.
3. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, Mors O, Maier W, Hauser J, Souery D, Placentino A, Zobel A, Larsen ER, Czerski PM, Gupta B, Hoda F, Perroud N, Farmer A, Craig I, Aitchison KJ, McGuffin P: Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009; 195:30-38.
4. Michaelovsky E, Frisch A, Rockah R, Peleg L, Magal N, Shohat M, Weizman R: A novel al-lele in the promoter region of the human serotonin transporter gene. Mol Psychiatry 1999; 4:97-99.
5. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taub-man J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D: Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78:815-826.
6. Serretti A, Calati R, Mandelli L, De Ronchi D: Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 2006; 7:1659-1669.
7. Bozina N, Jovanovic N, Podlesek A, Rojnic Kuzman M, Kudumija Slijepcevic M, Roguljic A, Dimitrovic A, Bozina T, Lovric J, Ljubic H, Medved V: Suicide ideators and attempters with schizophrenia-the role of 5-HTTLPR, rs25531, and 5-HTT VNTR intron 2 variants. J Psychiatr Res 2012; 46:767-773.
8. Uher R, McGuffin P: The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry 2008; 13:131-146.
9. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL: Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 2006; 11:224-226.
10. Martin J, Cleak J, Willis-Owen SA, Flint J, Shifman S: Mapping regulatory variants for the serotonin transporter gene based on al-lelic expression imbalance. Mol Psychiatry 2007; 12:421-422.
11. Lenze EJ, Goate AM, Nowotny P, Dixon D, Shi P, Bies RR, Lotrich FK, Rollman BL, Shear MK, Thompson PA, Andreescu C, Pollock BG: Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. J Clin Psychopharmacol 2010; 30:672-677.
12. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274:1527-1531.
13. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvox-amine. Mol Psychiatry 1998; 3:508-511.
14. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23:587-590.
15. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E: Factors affecting fluvoxamine antidepres-sant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50:323-330.
16. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, Ganapathy V, Leibach FH: Initial conditions of serotonin transporter kinetics and genotype: inf luence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51:723-732.
17. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L:5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopha rmacol 2003; 23:563-567.
18. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ: Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11:215-219.
19. Yoshida K, Ito K, Sato K, Takahashi H, Ka-mata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuro-psychopharmacol Biol Psychiatry 2002; 26:383-386.
20. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66:2621-2624.
21. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR: A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47:643-649.
22. Lesch K P, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, Riederer P: Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 1994; 95:157-162.
23. Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, Dwork AJ, Arango V: A serotonin transporter gene promoter polymorphism (5-HTTLPR) and pre-frontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000; 57:729-738.
24. Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J: Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 2000; 157:1700-1703.
25. Shioe K, Ichimiya T, Suhara T, Takano A, Sudo Y, Yasuno F, Hirano M, Shinohara M, Kagami M, Okubo Y, Nankai M, Kanba S: No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by pet. Synapse 2003; 48:184-188.
26. Serretti A, Artioli P, Quartesan R: Pharma-cogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 2005; 15:61-67.
27. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH: Influence of SERT-PR and STin2 in the serotonin transporter gene on the effect of selective serotonin reup-take inhibitors in depression: a systematic review. Mol Psychiatry 2004; 9:433-441.
28. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB: The serotonin transporter polymorphism, 5-HTTLPR, is associated with a faster response time to ser traline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004; 174:525-529.
29. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK: Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006; 296:1609-1618.
30. Taylor MJ, Sen S, Bhagwagar Z: Antidepres-sant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 2010; 68:536-543.
31. Joo EJ, Joo YH, Hong JP, Hwang S, Maeng SJ, Han JH, Yang BH, Lee YS, Kim YS: Korean version of the diagnostic interview for genetic studies: validity and reliability. Compr Psychiatry 2004; 45:225-229.
32. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296.
33. Kim JH, Choi SW, Joe SH, Ha TH, Yoo HJ, Choi JE, Cha B, Ha K: Reliability and validity of the Korean version of UKU-SERS-Pat in patients with bipolar disorder. Nord J Psychiatry 2008; 62:496-502.
34. Keller MB: Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003; 289:3152-3160.
35. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ: Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7:1115-1119.
36. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, Hirose T, Nanko S: Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997; 2:457-462.
37. Nakamura M, Ueno S, Sano A, Tanabe H: The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5:32-38.
38. Gelernter J, Kranzler H, Cubells JF: Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage dis-equilibria in African-and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 1997; 101:243-246.
39. Bellivier F, Henry C, Szoke A, Schurhoff F, Nosten-Bertrand M, Feingold J, Launay JM, Leboyer M, Laplanche JL: Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neurosci Lett 1998; 255:143-146.
40. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF: Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current 'next-step' pract ices. J Clin Psychiatry 200 0; 61:403-408.
41. Anderson IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J A ffect Disord 2000; 58:19-36.
42. Hachisu M, Ichimaru Y: Pharmacological and clinical aspects of fluvoxamine (dep-romel), the first selective serotonin reup-take inhibitor approved for clinical use employed in Japan. Nihon Yakurigaku Zasshi 2000; 115:271-279.
43. Srisurapanont M: Response and discontinuation rates of newer antidepressants: a meta-analysis of randomized controlled trials in treating depression. J Med Assoc Thai 1998; 81:387-392.
44. Lee BT, Ham BJ: Serotonergic genes and amygdala activity in response to negative affective facial stimuli in Korean women. Genes Brain Behav 2008; 7:899-905.
45. Gelernter J, Cubells JF, Kidd JR, Pakstis AJ, Kidd KK: Population studies of polymorphisms of the serotonin transporter protein gene. Am J Med Genet 1999; 88:61-66.
46. Wilkie MJ, Smith G, Day RK, Matthews K, Smith D, Blackwood D, Reid IC, Wolf CR: Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacoge-nomics J 2009; 9:61-70.
47. Reimherr F, Amsterdam J, Dunner D, Adler L, Zhang S, Williams D, Marchant B, Mi-chelson D, Nierenberg A, Schatzberg A, Feldman P: Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. Psychiatry Res 2010; 175:67-73.
48. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J: A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to anti-depressant treatment. Pharmacogenomics J 2007; 7:48-55.
49. Dogan O, Yuksel N, Ergun MA, Yilmaz A, Ilhan MN, Karslioglu HE, Koc A, Menevse A: Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test 2008; 12:225-231.
50. Damberg M: Transcription factor AP-2 and monoaminergic functions in the central nervous system. J Neural Transm 2005; 112:1281-1296.
51. Hu X, Oroszi G, Chun J, Smith TL, Goldman D, Schuckit MA: An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res 2005; 29:8-16.
52. Lipsky RH, Hu XZ, Goldman D: Additional functional variation at the SLC6A4 gene. Am J Med Genet B Neuropsychiatr Genet 2009; 15 0B:153.
53. Wendland JR, Moya PR, Kruse MR, Ren-Patterson RF, Jensen CL, Timpano KR, Murphy DL: A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. Hum Mol Genet 2008; 17:717-723.
54. Bonvicini C, Minelli A, Scassellati C, Bor-tolomasi M, Segala M, Sartori R, Giacopuzzi M, Gennarelli M: Serotonin transporter gene polymorphisms and treatment-resistant depression. Prog Neuropsychopharma-col Biol Psychiatry 2010; 34:934-939.
55. Braganca J, Eloranta JJ, Bamforth SD, Ibbitt JC, Hurst HC, Bhattacharya S: Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J Biol Chem 2003; 278:16021-16029.
56. Schosser A, Kasper S: The role of pharmaco-genetics in the treatment of depression and anxiety disorders. Int Clin Psychopharma-col 2009; 24:277-288.
57. Baumann P: Pharmacology and pharmaco-kinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 1996; 11(suppl 1):5-11.
58. Aronson S, Delgado P: Escitalopram. Drugs Today (Barc) 2004; 40:121-131.
59. Rao N: The clinical pharmacokinetics of es-citalopram. Clin Pharmacokinet 2007; 46:281-290.
60. Baumann P, Rochat B: Comparative phar-macokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995; 10(suppl 1):15-21.
61. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M: Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000; 157:1423-1428.
62. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M: Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995; 152:1500-1503.